NASDAQ:PSNL Personalis Q4 2023 Earnings Report $6.64 +0.41 (+6.50%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Personalis EPS ResultsActual EPS-$0.46Consensus EPS -$0.53Beat/MissBeat by +$0.07One Year Ago EPSN/APersonalis Revenue ResultsActual Revenue$19.68 millionExpected Revenue$19.56 millionBeat/MissBeat by +$120.00 thousandYoY Revenue GrowthN/APersonalis Announcement DetailsQuarterQ4 2023Date2/28/2024TimeN/AConference Call DateWednesday, February 28, 2024Conference Call Time5:00PM ETUpcoming EarningsPersonalis' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Personalis Q4 2023 Earnings Call TranscriptProvided by QuartrFebruary 28, 2024 ShareLink copied to clipboard.Key Takeaways The teleconference officially concluded. Participants were instructed to disconnect their lines. The company thanked everyone for their participation and wished them a great day. AI Generated. May Contain Errors.Conference Call Audio Live Call not available Earnings Conference CallPersonalis Q4 202300:00 / 00:00Speed:1x1.25x1.5x2xThere are 3 speakers on the call. Operator00:00:00ladies and gentlemen. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation and have a great day. Speaker 100:00:07Awesome. Thanks. Speaker 200:00:09Goodbye.Read morePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Personalis Earnings HeadlinesBrokerages Set Personalis, Inc. (NASDAQ:PSNL) Price Target at $7.67June 12, 2025 | americanbankingnews.comPersonalis: Ultra-Sensitive Tech, Ultra-Sensitive RisksJune 8, 2025 | seekingalpha.comAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. June 18, 2025 | Timothy Sykes (Ad)Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOJune 4, 2025 | finance.yahoo.comPersonalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOJune 3, 2025 | businesswire.comPersonalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-TherapyJune 3, 2025 | insidermonkey.comSee More Personalis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Personalis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Personalis and other key companies, straight to your email. Email Address About PersonalisPersonalis (NASDAQ:PSNL) develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.View Personalis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 3 speakers on the call. Operator00:00:00ladies and gentlemen. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation and have a great day. Speaker 100:00:07Awesome. Thanks. Speaker 200:00:09Goodbye.Read morePowered by